Rhenman & Partners Asset Management Ab acquired 220,000 shares as Ariad Pharmaceuticals Inc (ARIA)'s stock 0.00%. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.14) by $0.13. Shafer Bradford J had sold 26,829 shares worth $854,772 on Friday, March 3. It has outperformed by 73.15% the S&P500.The move comes after 5 months negative chart setup for the $1.30B company. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company's stock worth $236,000 after buying an additional 443 shares during the last quarter. The institutional investor held 65,900 shares of the beverages (production and distribution) company at the end of 2016Q4, valued at $6.85 million, up from 50,300 at the end of the previous reported quarter. The firm's market cap is $1.59 billion. About 598,681 shares traded. Kimberly Clark Corp (NYSE:KMB) has risen 0.32% since August 8, 2016 and is uptrending. It has underperformed by 12.95% the S&P500.
Total shares held by institutions as of the most recent company filings are 43,237,769 with a reported 3,124,974 bought and 423,045 sold. The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $5.07 million. Therefore 72% are positive. Needham & Company LLC lifted their price objective on shares of Theravance Biopharma from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, May 11th. As per Wednesday, June 21, the company rating was maintained by BMO Capital Markets. Credit Suisse maintained it with "Buy" rating and $4400 target in Wednesday, June 28 report. The firm earned "Hold" rating on Monday, June 27 by Societe Generale. For the week, the stock is performing -6.70%. The stock has "Underperform" rating by Robert W. Baird on Wednesday, October 12. As per Wednesday, August 2, the company rating was maintained by Needham. The rating was upgraded by Argus Research to "Buy" on Tuesday, November 15. Therefore 88% are positive. Ariad Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. (NASDAQ:TBPH) is seeing declines so far in today's trading session. Leerink Swann initiated the shares of TBPH in report on Thursday, May 12 with "Outperform" rating. On Monday, August 29 the stock rating was initiated by Evercore with "Buy". Robert W. Baird maintained Theravance Biopharma Inc (NASDAQ:TBPH) rating on Wednesday, August 12. On average, equities research analysts forecast that Theravance Biopharma will post ($4.61) EPS for the current year. The stock of Theravance Biopharma Inc (NASDAQ:TBPH) has "Buy" rating given on Wednesday, July 19 by Cantor Fitzgerald. Robert W. Baird has "Neutral" rating and $14 target.
Ameritas Investment Partners Inc. increased its stake in shares of Theravance Biopharma by 1,494.3% in the first quarter. Its down 0.28, from 1.24 in 2016Q3. It increased, as 20 investors sold TBPH shares while 13 reduced holdings. Omers Administration reported 0% in Theravance Biopharma Inc (NASDAQ:TBPH). About shares traded. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 89.85% since August 9, 2016 and is uptrending. Voya Invest Mngmt Limited Liability Company holds 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH) for 14,883 shares.
Theravance Biopharma, Inc.(NASDAQ:TBPH)'s stock has performed at -6.56% year to date.
Theravance Biopharma (TBPH) opened at 29.79 on Thursday. 509,083 are held by Foundation Asset Mngmt Limited Partnership. Millennium Limited Co invested 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Steinberg Global Asset Mgmt holds 0.1% or 47,100 shares in its portfolio. American International Group Inc Inc has 20,859 shares for 0% of their portfolio. Deutsche Commercial Bank Ag, Germany-based fund reported 78,707 shares. Swiss Fincl Bank accumulated 63,342 shares.
Theravance Biopharma, Inc.'s RSI is 14.21. "Reports Second Quarter 2017 Financial Results and ..." on August 08, 2017.
More notable recent Theravance Biopharma Inc (NASDAQ:TBPH) news were published by: Prnewswire.com which released: "Theravance Biopharma to Report Second Quarter 2017 Financial Results and ..." on August 01, 2017, also Prnewswire.com with their article: "Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President ..." published on July 31, 2017, Prnewswire.com published: "Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study ..." on August 02, 2017.
Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $1.30 million activity. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/09/theravance-biopharma-inc-nasdaqtbph-stake-cut-by-tiaa-cref-investment-management-llc-updated-updated.html.